Quantcast

Reportlinker Adds World Cancer Therapies Market Report

September 10, 2009

NEW YORK, Sept. 10 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

World Cancer Therapies Market

http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html

This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006 through 2015. A six-year historic analysis is also provided. The report profiles 207 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Imclone Systems, Inc., Merck KGaA, Novartis AG, Ortho Biotech Products, L.P, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Schering Plough Corporation, Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited, and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CANCER THERAPIES

A GLOBAL STRATEGIC BUSINESS REPORT MCP-1551

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-2

Product Definitions and Scope of Study I-3

Chemotherapy I-3

Targeted Therapy I-3

Hormonal Therapy I-3

Immunotherapy I-3

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

Cancer Therapies: A Prelude II-1

Patent Expiries of Branded Drugs to Trigger Generic Competition II-1

New Cancer Therapies Appear Over the Horizon II-2

New Generation Cancer Drugs and Their Area of Use II-2

The New Era of Cancer Treatment II-3

Biotech Cancer Therapies Yet to Overcome Teething Issues II-3

Table 1: Global Market for Biotech-Enabled Cancer Therapies

(2004 & 2008): Percentage Breakdown of Revenues by

Application – Hematological, Solid Tumors, and Conditions

related to Chemotherapy (includes corresponding

Graph/Chart) II-3

Targeted Therapy: The New Frontier of Cancer Treatment II-3

Top Rated Targeted Cancer Therapeutics with the Potential

to become Blockbuster Drugs Include: II-4

Oncology Drugs Approved for Use in the Targeted Cancer

Therapeutics Sector in the years 2006, 2007, and 2008. II-4

Table 2: Molecular Targeted Therapies Worldwide:

Percentage Breakdown of Molecular Targeted Therapies Under

Pipeline by Drug Class as of 2006 (includes corresponding

Graph/Chart) II-5

Combination Therapy: A Double Whammy Success II-5

Small Cap Companies: A Target of Private Capital Financing II-5

Drugs (that are both available and under pipeline)

Developed by the Four Small-Cap Companies II-6

Table 3: Venture Capital Investment (In US$ Millions) Made

in Research and Development of Biotechnology for the years

2004 and 2009 (includes corresponding Graph/Chart) II-7

Shifting Therapeutic Preferences II-7

Table 4: Global Market for Antihormonal Therapy (2005 and

2014): Percentage Breakdown of Revenues by Drug Class – LHRH

Analogs, Aromatase Inhibitors, Anti-androgens,

Anti-estrogens, and Other Hormone Antagonists(includes

corresponding Graph/Chart) II-8

Innovations in Cancer Drug Delivery: A Key Factor in Product

Differentiation II-8

Personalized Medicine: Gain in Importance II-8

Growth Drivers In a Capsule II-9

Rise in Cancer Incidences & Access to Modern Therapeutics

Foster Growth II-9

Demographics & Lifestyles Raise the Risk of Cancer II-9

Cancer Prone Sites based on Age II-10

Table 5: Population of People Aged More than 65 Years in

United States for the years 2000, 2010, and 2020 (includes

corresponding Graph/Chart) II-10

Unmet Needs Leave Scope for Further Research and Development II-10

Low Entry Barriers in Cancer Research Encourages

Breakthrough Developments II-10

Increasing Investments by National Health Authorities II-11

Efficiency & High Prices Magnetize Manufacturers II-11

Supportive Cancer Drugs Contribute to Growth II-11

Improved Screening, Diagnosis & Patient Survival Rates

Trigger Growth II-11

Table 6: Global Cancer Diagnostics Market (2004): Breakdown

of Sales by Geographic Region (In US$ Billion) (includes

corresponding Graph/Chart) II-12

Molecular Imaging of Cancer: Critical in Improving Patient

Outcomes II-12

Innovations, Improvements, and Approvals Propel Growth II-13

Growth Restraints II-13

High Prices of Targeted Therapies Act as a Speed Breaker II-13

Table 7: Average Costs of Cancer Therapies in the US as of

the Year 2005 in US$ II-14

Limited Tumor Specificity and Toxicity II-14

Complicated Treatment Protocols: A Major Stumbling Block in

Patient Compliance II-14

Reduced Smoking II-14

Reimbursement and Coverage Remains a Major Challenge II-15

Changes in Reimbursement Policies Influence Market Prospects II-15

Multiple Drug Resistance II-15

Stringent Regulations Delay Market Approval II-16

Challenges Encountered in Clinical Trials II-16

High Development Costs Retracts Manufacturers in Developing

Countries II-16

Notes From Across the Globe II-16

United States II-16

Medicare Restructures its Coverage for Chemotherapy II-16

Personalized Care for Cancer Treatment in US II-17

Drugs in Development in the US II-17

Chemotherapy Drugs Undergoing Trials for Breast Cancer

Treatment in United States (as of 2007) II-17

Hormonal Therapy Drugs Undergoing Trials for Breast Cancer

Treatment in United States (as of 2007) II-18

Targeted Therapy Drugs Undergoing Trials for Breast Cancer

Treatment in United States (as of 2007) II-18

Statistical Findings II-19

Table 8: US Market for Hospital Cancer Therapies (2004 and

2009): Percentage Breakdown of Revenues by Treatment Type

- Surgery, Chemotherapy Drugs, Radiation Therapy,

Biotechnology-Based Drugs, and Others (includes

corresponding Graph/Chart) II-19

Table 9: US Demand for Chemotherapy Drugs (2004 and 2009):

Percentage Breakdown of Revenues by Drug Class -

Alkylating Agents & Related, Antimetabolites & Related,

Mitotic Inhibitors, and Others (includes corresponding

Graph/Chart) II-19

Table 10: US Market for Multiple Myeloma (2006): Percentage

Revenue Breakdown of Leading Players – Celgene

Corporation, Millennium Pharmaceuticals, Inc., Ortho

Biotech, and Others (includes corresponding Graph/Chart) II-20

Table 11: New Cancer Cases and Deaths in United States in

the year 2006 (includes corresponding Graph/Chart) II-20

Table 12: US Market for Cancer Therapies (2004): Percentage

Revenue Breakdown of Leading Players – Genentech,

Sanofi-Aventis, AstraZeneca, Bristol-Myers Squibb, Pfizer,

Eli Lilly, Novartis, Roche and Others (includes

corresponding Graph/Chart) II-21

Table 13: US Market for Breast Cancer Therapeutics (2006):

Percentage Breakdown of Revenues by Segment: Cytotoxic

Therapeutics, Hormonal Therapeutics, and Targeted

Therapeutics (includes corresponding Graph/Chart) II-21

Canada II-22

Table 14: New Cases of Cancer Incidences and Deaths in

Canada in the year 2006 (includes corresponding Graph/Chart) II-22

Australia II-23

Asia II-23

India II-23

Japan II-24

Korea II-24

Malaysia II-24

Table 15: Imports of Cancer Diagnostic and Therapy

Equipment (2004): Percentage Breakdown of Import Value by

Country of Origin (includes corresponding Graph/Chart) II-24

Europe II-24

Advancements in Breast Cancer Treatment in Europe II-25

New Formulations that are Under Clinical Trials II-25

Table 16: European Market for Breast Cancer Therapeutics

(2006): Percentage Breakdown of Revenues by Drug Class:

Cytotoxic Drugs, Hormonal Drugs, and Biologics (includes

corresponding Graph/Chart) II-26

Drugs Undergoing Trials for Bladder Cancer Treatment in

Europe As of 2006 II-26

Latin America II-27

Brazil II-27

Mexico II-27

Argentina II-27

Cancer Incidences Worldwide II-28

Table 17: New Incidences of Liver Cancer (in ’000) Worldwide

for the years 2008 and 2012 II-28

Table 18: New Incidences of Breast Cancer (in ’000)

Worldwide for the years 2008 and 2012 II-29

Table 19: New Incidences of Prostate Cancer (in ’000)

Worldwide for the years 2008 and 2012 II-30

Table 20: New Incidences of Bladder Cancer (in ’000)

Worldwide for the years 2008 and 2012 II-31

2. Product Overview II-32

Cancer: A Major Health Crises in the Modern World II-32

Table 21: Cancer Causes in Developed and Developing Countries

(2006): Percentage Breakdown by Risk Factors – Diet or

Nutrition, Infections, Tobacco, and Other Factors (includes

corresponding Graph/Chart) II-32

Types of Cancers II-32

Prostate Cancer II-33

Key Prostate Cancer Drugs & Companies II-33

Breast Cancer II-33

Key Breast Cancer Drugs & Companies II-34

Cervical Cancer II-34

Colorectal Cancer II-34

Key Colorectal Cancer Drugs & Companies II-35

Lung Cancer II-35

Key Lung Cancer Dugs & Companies II-36

Renal Cancer II-36

Key Renal Cancer Drugs and Companies II-36

Skin Cancer II-36

Non-Hodgkin’s Lymphoma II-37

Leukemia II-37

Pancreatic Cancer II-37

Bladder Cancer II-37

Endometrial Cancer II-37

Cancer Therapies: A Review II-37

Monoclonal Antibodies Open Up A New Era in Cancer Treatment II-38

List of Approved Monoclonal Antibodies Used in Treating

Various Cancers II-38

Therapeutic Cancer Vaccines: Harnessing the Immune System to

Fight Cancer II-39

Cancer Vaccine Strategies II-39

Therapeutic Cancer Vaccine Products Under Clinical Trials

as of 2007 II-40

Gene Therapy II-40

Types of Cancer Therapies II-40

Chemotherapy II-40

Chemotherapy Drugs Require Careful Handling II-41

Types of Chemotherapy II-41

Chemotherapy Drug Classes II-42

Risks Associated with Chemotherapy II-42

When Chemotherapy Fails II-43

Targeted Therapy II-43

Table 22: Targeted Therapies Market Worldwide (2006):

Percentage Breakdown of Targeted Therapeutic Drugs Under

Various Stages of Development (includes corresponding

Graph/Chart) II-44

Hormonal Therapy II-44

Hormonal Therapy Strategies II-44

Drug Classes in Hormone Therapy II-45

Drugs Used in Hormone Therapy and Their Uses II-45

Side-Effects Associated with the Use of Various Drugs in

Hormone Therapy II-46

Immunotherapy II-46

A Primer II-46

Immunotherapy Treatment Strategies II-47

Second-Generation Immunotherapies II-48

Table 23: Global Market for Immunotherapy (2007 and 2012):

Percentage Breakdown of Revenues by Drug Class -Monoclonal

Antibodies, Biological Response Modifiers, Vaccines, and

Other Immunotherapy Products (includes corresponding

Graph/Chart) II-48

3. Drug Approvals and Clinical Trials II-49

ABRAXANE Gains Marketing Approval in Korea, Australia and

Other Countries II-49

GlaxoSmithKline’s Cervarix Finds Place in UK National

Immunization Programme II-49

Biogen Idec and Elan Commence Clinical Trial of TYSABRI II-50

Calistoga Pharmaceuticals Starts Phase I Clinical Trial of

CAL-101 II-50

Progen Pharmaceuticals Continues Phase 1 Development of PG-11047 II-50

GlaxoSmithKline Receives Conditional EU Approval for

Marketing Lapatinib II-50

Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer

Treatment II-50

Genentech Secures FDA Approval for Avastin II-51

EU Approves Four Biosimilar Versions of Neupogen II-51

Russia Approves Oncophage for Kidney Cancer Treatment II-51

Eisai to Start Clinical Testing of MORAb-028 II-51

Threshold Pharmaceuticals Starts Phase I/II Clinical Trials

of TH-302 II-51

AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6 II-51

GSK’s Tykerb Receives USFDA Approval II-52

Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40

with Gemzar and Rituxan II-52

S*Bio Initiates Phase I Clinical Trials of SB1518 II-52

Merck Serono Initiates Phase III Trials of Cladribine II-52

BioCurex Receives Patent for RECAF Technology Applications II-52

Chidamide/HBI-8000 Completes Phase I Clinical Trials in China II-52

AVEO Initiates Phase I Trials of AV 299 II-53

Exelixis Completes Phase I Trials of XL765 II-53

Infinity Pharmaceuticals Starts Phase I Clinical Trial of

IPI-926 II-53

Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX II-53

GTx Completes Phase II Clinical Trials of Ostarine II-53

Imclone Awaits Approval for Erbitux from US Medicine Regulator II-54

Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of

Nimotuzumab II-54

Peplin Starts Phase III Clinical Trials of PEP005 Gel II-54

ERBITUX Receives Marketing Approval in Japan II-54

Progenics Starts Phase I Clinical Study of PSMA ADC II-54

FDA Awards Orphan Drug Designation for the Use of Stem Cell

Technology in Bone Marrow Transplantations II-54

Roche, OSI and Chugai Receive Approval for Tarceva in Japan II-55

Eisai Receives FDA Approval for ONTAK(R) II-55

Genmab Terminates the Development of HuMax-CD4 II-55

Teva Pharmaceutical Acquires EU Authorization to Market

Neutropenia Drug II-55

Novartis’ Everolimus Awaits Approvals from US FDA,

Swissmedic, and EMEA II-55

Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-

cancer Drug Studies II-56

Sanofi-Aventis Receives Japanese Approval for Taxotere(R)

Injection II-56

Roche’s Avastin Bags European Approval for Renal Cancer

Treatment II-56

Roche Announces European Approval of Herceptin II-56

GSK’s Hycamtin Obtains FDA Approval II-57

Avastin Receives European Approval for Breast Cancer Treatment II-57

Roche’s Tarceva Obtains European Approval II-57

Roche’s NeoRecormon Gains European Approval II-57

Northwest Biotherapeutics’ DCVax-Brain Gains Swiss Approval II-57

Alfacell’s ONCONASE Receives Orphan Drug Designation from US II-58

Cougar Biotechnology Commences Phase II Trial of CB7630 II-58

Lorus Therapeutics Receives Orphan Drug Designation for its

LOR-2040 II-58

Merck Serono Receives EU Approval for mCRC Treatment With

Erbitux II-58

MGI PHARMA and HELSINN Receive FDA Approval for Aloxi II-58

FDA Grants Approval for Sutent, a Kidney and Gastrointestinal

Cancer Drug II-58

Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval II-59

Dabur Pharma Acquires FDA Approval for Paclitaxel Injection II-59

EUSA’s CAPHOSOL Finds Application in Treating Oral Mucositis II-59

European Commission Approves Amgen’s Vectibix for Metastatic

Colorectal Cancer II-59

GPC Biotech Starts Phase 2 Trials of Satraplatin plus with

Tarceva II-59

FDA Approves Vectibix as Treatment for Metastatic Colorectal

Cancer II-60

FDA Approves IND Indication for CYT-500 of Cytogen II-60

FDA Clears Rituxan for New Indications II-60

Epeius Receives BFAD Approval for Expanded Access Program for

Rexin- G II-60

BioMedicines Initiates Phase 1b Study of Biomed 101 II-61

Avastin Obtains FDA Approval for Treating Recurrent

Colorectal Cancer II-61

Genentech’s Herceptin Gains FDA Nod for Treating Early stage

Cancer after Surgery II-61

Epeius Starts Phase I and II Trials of the New Tri-Rex

Vaccination Protocol II-62

Sonus Begins Phase 1 Clinical Trial of TOCOSOL(R) Camptothecin II-62

Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist

Combined with Chemotherapy Regimen II-62

Morphotek’s MORAb-009 Receives Orphan Drug Designation II-62

Morphotek’s MORAb-003 Receives Orphan Drug Status from the US

FDA II-63

Morphotek Grants FDA Approval of the IND for MORAb-009 II-63

MannKind Receives IND Clearance for MKC1106-PP Immunotherapy II-63

Pharmexa Initiates Phase II trials of GV 1001 II-64

Wyeth Pharmaceuticals Declares Discontinuation of Phase III

Clinical Trials for Temsirolimus II-64

OXiGENE Announces Clinical Trials of CA4P II-64

Glaxo Smith Kline’s Hycamtin Gains FDA Approval for Treating

Cervical Cancer II-64

Cell Genesys Announces the Initiation of Amplified Phase I

Trial of CG0070 II-65

Genentech’s Avastin Receives FDA Approval for Lung Cancer

Treatment II-65

Vorinostat Acquires FDA Approval for Skin Cancer Treatment II-65

Callisto Launches the First Clinical Trial of Landmark

Discovery, L-Annamycin for ALL II-65

Shanghai Sunway Biotech’s H101 Receives Marketing Approval in

China II-66

Northwest Biotherapeutics Gains Patent for CXCR4 II-66

Biocon’s Cancer Drug Initiates Phase II Trials II-67

4. New Drug Developments and Launches II-68

GSK Launches Cervarix in Singapore II-68

Abeome Launches New Stem Cell Monoclonal Antibody II-68

Dabur Pharma Launches a New Drug Delivery System, Nanoxel II-68

Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs II-68

Monash University Scientists Develop siRNA for Cancer Treatment II-69

Cytogen Introduces SOLTAMOX(TM), the First Hormonal Breast

Cancer Therapy II-69

5. Recent Industry Activity II-70

Avexa to Acquire Progen Pharmaceuticals II-70

Abraxis Takes Over Platco and Shimoda II-70

WEHI Collaborates with Abbott and Genentech II-70

Novartis Inks a Production Deal with Lonza II-70

Roche to Take Over UK-Based Biotech Company, Piramed II-71

Pfizer Acquires Encysive II-71

Eden Biodesign Inks a Marketing Services Deal with Human

Genome Sciences II-71

FivePrime Join Hands with Pfizer for Cancer and Diabetes

Research II-71

Sanofi-Aventis and Dyax Ink Two Antibody Pacts II-72

Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110 II-72

Takeda Inks an Exclusive Partnership Agreement with Amgen II-73

Genentech and Roche Ink a Licensing Agreement with Glycart II-73

Bristol-Myers Squibb to Acquire Kosan Biosciences II-73

Nabi Biopharmaceuticals Collaborates with NIAID II-73

Pfizer to Acquire Serenex II-74

Morphotek Signs an Agreement with Pivotal BioSciences II-74

GE Healthcare Inks a Three-Year Agreement with Eli Lilly II-74

ArQule Signs Two Agreements with Daiichi Sankyo II-74

Circadian Completely Acquires Vegenics Limited II-75

Lpath Inks an Accord with Merck Serono II-75

Topex Expands its Distribution Deal with Therapy Remarketing II-75

Unibioscreen Inks a Partnership Agreement with Drais

Pharmaceuticals II-75

Avant Immunotherapeutics to Become Celldex Therapeutics II-75

Abraxis Enters into Definitive License Agreements with

ProMetic Life Sciences II-76

Biovest International to Receive US$1.6 Million Funding for

Biomedical Research II-76

Access Completes the Acquisition of Somanta II-76

Clinical Data Inks an Agreement to Take Over Avalon

Pharmaceuticals II-76

EUSA Pharma Acquires Cytogen Corporation II-77

Oncologic Merges with Triton BioSystems II-77

Eli Lilly to Take Over ImClone Systems II-77

CEL-SCI Establishes a New Manufacturing Unit II-77

ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary II-78

Takara Bio Signs a Research Agreement with a Chinese University II-78

Shanghai Roche Expands its MabThera Marketing Activities II-78

Merck Completes the Acquisition of Majority Stake in Serono II-78

Merck Enters into Licensing and Collaboration Agreement With

Idera II-78

Sanofi-Aventis Inks a Global Licensing Deal with Oxford

BioMedica II-79

WEHI to Collaborate with Genentech and Roche II-79

AstraZeneca Acquires MedImmune II-79

Antisoma Enters into a Global Accord with Novartis II-79

Sanofi-Aventis and Astellas Pharma to Restructure their JV

Operations in Japan II-79

Biomira Amends its Agreements with Merck II-80

AstraZeneca Takes Over Canadian Biologics Plant II-80

Pfizer to Acquire Coley Pharmaceutical Group II-80

Abraxis Takes Over Watson’s Manufacturing Facility II-80

Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility II-81

Bristol-Myers Squibb to Take Over Adnexus Therapeutics II-81

Merck to Partner with a Florida-based Research Center II-81

Organon to Partner with Medarex II-81

Genzyme to Acquire Bioenvision II-82

Genentech Inks a Deal with Seattle Genetics II-82

TopoTarget Takes Over Apoxis II-82

Roche to Acquire CuraGen’s Subsidiary II-82

GPC Biotech Inks an Agreement with Yakult II-82

MediGene Acquires Avidex II-82

Sanofi-Aventis Inks an Agreement with Taiho II-83

Biogen Inks Merger Agreement with Conforma II-83

Roche Signs a Merger Agreement with Ventana II-83

Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile II-84

ImClone Systems and Merck Revise ERBITUX Agreement II-84

GSK Invests euros 500 Million in France II-84

Amgen Takes Over Avidia II-84

Moores Cancer Center Collaborates with Medarex II-84

ADITUS Medical Forms an Alliance with IGEA II-85

Callisto Opens Site For Phase-II Clinical Trials of Atiprimod II-85

XOMA Inks an Agreement with Attenuon II-85

AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug II-85

Nventa To Procure Hiltonol from Oncovir Incorporated II-86

MaxCyte and Medinet Sign an Agreement for Immuno-Cell Therapy II-86

Receptor Acquires Cancer Vaccine ‘G17DT’ from Aphton II-86

Enzon Collaborates with Santaris for Joint Development ff

Novel RNA Antagonists II-87

Epeius Receives Funding from Lazarex for Rexin-G(TM) Trials II-87

Callisto Inks a Deal with M.D. Anderson Cancer Center II-87

AstraZeneca Inks an Agreement with Abraxis BioScience II-88

diaDexus and BVF Establish CFD Therapeutics II-88

Merck to Acquire US Rights for Liposome Vaccine II-88

Genentech Enters Into Alliance with Inotek II-89

AstraZeneca to Take Over KuDOS Pharmaceuticals II-89

Genentech Collaborates with Accelerate Brain Cancer Cure II-89

Sonus and Schering Enter into a Global Licensing Agreement II-90

Abgenix Inks Merger Agreement with Amgen II-90

AstraZeneca and Astex Enter into an Alliance II-91

Pfizer Inks Global License Pact with Coley Pharmaceutical Group II-91

Genzyme Takes Over ILEX Oncology II-91

Genentech and CGI Enter into an Exclusive Agreement II-92

Genzyme to Acquire AnorMED II-92

6. Focus on Select Players II-93

Abraxis BioScience, Inc. (USA) II-93

Amgen, Inc. (USA) II-93

AstraZeneca PLC (UK) II-93

Bayer Schering Pharma (Germany) II-95

Biogen Idec Inc (USA) II-95

Bristol-Myers Squibb Company (USA) II-96

Celgene Corporation (USA) II-96

Cell Therapeutics, Inc. (USA) II-96

Cephalon, Inc. (USA) II-97

Chugai Pharmaceutical Co., Ltd. (Japan) II-97

Eli Lilly and Company (USA) II-98

F. Hoffmann-La Roche Ltd (Switzerland) II-98

Genentech, Inc. (USA) II-99

Genzyme (USA) II-99

GlaxoSmithKline (UK) II-99

Imclone Systems, Inc (USA) II-101

Merck KGaA (Germany) II-101

Novartis AG (Switzerland) II-102

Ortho Biotech Products, L.P (USA) II-103

OSI Pharmaceuticals, Inc. (USA) II-103

Pfizer (USA) II-103

Sanofi-Aventis (France) II-104

Schering Plough Corporation (USA) II-105

Seattle Genetics, Inc. (USA) II-105

Takeda Pharmaceutical Company Limited (Japan) II-105

Wyeth (USA) II-106

7. Market Perspective II-107

Table 24: Global Recent Past, Current & Future Analysis for

Cancer Therapies by Type – Targeted Therapy, Chemotherapy,

Hormone Therapy, and Immunotherapy Markets Independently

Analyzed with Annual Sales Figures in US$ Billion for Years

2006 through 2015 (includes corresponding Graph/Chart) II-107

Table 25: Global Historic Review for Cancer Therapies by Type -

Targeted Therapy, Chemotherapy, Hormone Therapy, and

Immunotherapy Markets Independently Analyzed with Annual

Sales Figures in US$ Billion for Years 2000 through 2005

(includes corresponding Graph/Chart) II-107

Table 26: Global 10-Year Perspective for Cancer Therapies by

Type – Percentage Breakdown of Dollar Sales for Targeted

Therapy, Chemotherapy, Hormone Therapy, and Immunotherapy

for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-108

III. COMPETITIVE LANDSCAPE

To order this report:

World Cancer Therapies Market

http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus